Optimizing Tableting Processes with Quality by Design - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Optimizing Tableting Processes with Quality by Design
A technical forum featuring Tim Freeman of Freeman Technology and Carl Levoguer of Malvern Instruments.


Pharmaceutical Technology
Volume 36, Issue 5, pp. 48-55

PharmTech: Can you offer any best practices for those beginning to apply a QbD approach to tableting and granulation?

Freeman (Freeman Technology): QbD relies heavily on engineering an optimized, well-understood process. It is therefore important, from the outset, to work out how to gather analytical data that will accurately reflect process performance. Effective powder handling is central to the success of tableting, granulation and a wide range of other pharmaceutical unit operations. Appropriate powder characterization techniques are, therefore, an essential prerequisite.

The number of powder testing techniques available reflects both the importance of such testing and its difficulties. When choosing which techniques to apply for QbD studies, I would suggest assessing against a number of criteria including:

  • reproducibility and sensitivity
  • process relevance
  • ease of use.

Levoguer (Malvern Instruments): One of the biggest challenges for those applying QbD is how to access and gather the necessary information. The full implementation of QbD demands a comprehensive understanding of process and product, and the identification of an effective control strategy for the manufacturing process. Choice of analytical instrumentation is therefore crucial.

With well-established techniques such as laser diffraction particle-size measurement, customers can rightly expect the highest levels of automation and analytical productivity. Some systems can extend the efficiencies of dry measurement to more samples and combine rapid measurement times with assured data quality, to push analytical productivity to high levels for all users.

Of equal importance, however, are continuous laser diffraction particle size analyzers that offer real-time measurement for pilot-scale studies and commercial plant monitoring and control. These systems can significantly accelerate QbD studies. Running a pilot plant with real-time monitoring in place enables consistent control at the experimental conditions of interest and makes the impact of changes in operating variables instantly obvious.

For some types of analysis, the technology is newer, but it is vital to recognize what can now be achieved. Returning to the example of morphologically directed imaging, these systems involve considerable investment but can deliver significant value over the long term. Being able to measure not just size and shape but also the distribution of different chemical species within a dispersed sample, such as a disintegrated tablet, can be invaluable when trying to really understand how the process works and how to optimize it.

References

1. X. Fu et al., Particuology 10 (2), 203–208 (2012).

2. J. Khoo et al., "Use of Surface Energy Heterogeneity to Relate the Effect of Surface Modification to Powder Properties" (Freeman Technology website, 2012), http://www.freemantech.co.uk/goto.php?link=ART_POSTER_02/, accessed Apr. 16, 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here